Loading stock data…
$23.41-1.02 (-4.18%)
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Beam Therapeutics Inc. in the Healthcare sector is trading at $23.41 with a market capitalization of $2.5B. Wall Street consensus targets $52.15 (13 analysts), implying a +122.8% move over the next 12 months. The stock is currently near its 52-week low of $20.23, remaining 17.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $490,000↓ | $31.74M↓ | $114.11M↑ | $9.70M↑ | $8.47M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$126.55M↓ | -$107.22M↓ | -$17.45M↑ | -$126.81M↓ | -$120.15M |
| Net Income | -$122.68M↓ | -$94.32M↓ | $244.30M↑ | -$112.73M↓ | -$102.14M |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogen...